

Mailing Address: P.O. Box 5119 | Helena, MT 59604 Phone: 406.443.6002 | Toll-free: 1.800.395.7961 Fax: 406.513.1928 | Toll-free: 1.800.294.1350

Montana Healthcare Programs Prior Authorization Request Form for Use of Nasal CGRP Inhibitors

	Memb	er Name:	DOB:	Date:
-	Memb	er ID:	Prescriber Phone:	Prescriber Fax:
-	Prescriber Name:		Prescriber Specialty (if applicable):	
-	Requested Drug: ☐ Zavzpret® (Approval subject to preferred drug list requirements)		Dose:	
Pl	ease co	omplete below information for applicable sit	uation, Initiation or Con	tinuation of therapy:
	INIT	IATION OF THERAPY		
	1.	Member is 18 years of age or older: ☐ Yes ☐ N	o	
	2.	Member has diagnosis of acute migraine with or v	without aura: ☐ Yes ☐ No	
	3.	Member must currently be using a prophylactic m not tolerated or ineffective (Note: member CANN peptide [CGRP] therapy for preventative therapy)	OT be on an oral or injectab	
		☐ Yes - Therapy name:		
		□ No - Explanation required:		
	4.	Member must have an inadequate response, contra 5-HT1 receptor agonists, ONE of which must be a		at least two (2) different triptan
		Drug name:	Dates u	ısed:
		Drug name:	Dates u	used:
	5.	If nonpreferred, member has had a trial and inaded the same indication and the same mechanism of a Healthcare Programs Preferred Drug List 19 (mt.	ction (CGRP receptor antago	
		Drug name:	Dates u	used:
	6.	Provider attests Zavzpret® is being used for acute migraine: ☐ Yes ☐ No	treatment of migraine and r	not for preventative treatment of
	7.	Provider attests Zavzpret® will not be used in cor	mbination with other CGRP	agents: ☐ Yes ☐ No
Li	mitatio	ns:		

Li

- Maximum daily dose: 1 spray daily
- Maximum monthly limit: 1 box (6) per month

Initial authorization will be issued for 1 year.

CC	ONTINUATION OF THERAPY		
1.	Member has experienced a positive response to therapy: ☐ Yes ☐ No		
2.	Member is currently using a prophylactic medication unless contraindicated, not tolerated, or ineffective: ☐ Yes ☐ No		
	Action required – Please indicate the current prophylactic therapy:		
3.	Provider attests Zavzpret® is being used for acute treatment of migraine and not for preventative treatment of migraine: \square Yes \square No		
4.	Provider attests Zavzpret® will not be used in combination with other CGRP agents: ☐ Yes ☐ No		
	Reauthorization will be issued for 1 year.		

Please complete form, including required attachments and fax to: $1\hbox{-}800\hbox{-}294\hbox{-}1350$

10/2023